| Anti-angiogenesis Program |
|
| Angiogenesis is a normal process of developing new blood vessels. Tumor angiogenesis is the infiltration of new blood vessels needed for tumor growth. Anti-angiogenic therapeutics fight cancer by restricting the growth of blood vessels through the inhibition of the signals that are essential for this vascular growth. In 2006, sales of anti-angiogenic therapies (Sutent®, Nexavar®, Avastin®, Erbitux®, and others) exceeded $4.6B worldwide. |
|
| Xcovery is developing a next-generation small-molecule anti-angiogenesis therapeutic targeting multiple receptor tyrosine kinases.
The Xcovery program is built upon the experience of Dr. Chris Liang, an expert in tyrosine kinase signaling. Driven by increased selectivity and better target and off-target knowledge, the program's design objectives are to surpass existing therapies such as Sutent®, Nexavar®, or Avastin® in efficacy with decreased toxicity. |
|
| The anti-angiogenesis program is unique in that it targets all isoforms of the vascular endothelial growth factor receptor, VEGFR 1, 2, and 3 (also sometimes referred to as FLT1, KDR/Flk1, and FLT4,) and all isoforms of the platelet derived growth factor receptor, PDGFR alpha and beta. It is expected that specifically inhibiting all five of these kinases will produce a more significant therapeutic effect, increasing efficacy and reducing toxicity, which is a problem of current VEGFR-targeting therapies. |
| |
|